XAGE (Carmell Corp) Debt to Equity
Longevity Health Holdings (XAGE) management is betting on biochemical innovations for tissue regeneration and anti-aging via the premium segment. The operational resilience of the clinic network is supported by direct patient payments, ensuring rapid capital turnover. This chart illustrates the asset's market value with the 0.00 indicator, confirming the brand's strong pricing power driven by the unique Carmell Plasma Matrix platform.
%20All%20Debt%20to%20Shareholders'%20Equity%20Ratio&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_XAGE_-_Longevity-Health-Holdings_-_All-Debt-to-Shareholders-Equity-Ratio "XAGE (Longevity Health Holdings Inc) Total Debt to Capital history from 03/11/2025 to 09/27/2025 | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Carmell Corp (XAGE)
To identify the sector's fundamental leaders, the analyst evaluates financial stability via the share of debt capital within the asset structure. This metric measures the business's dependence on creditors relative to equity, which is critical for Longevity Health Holdings (XAGE) when financing tissue regeneration research; therefore, the total debt-to-equity ratio allows for an assessment of the balance between debt load and investments in innovation.